Biotech Horama Raises 19M€ to Treat Retinitis Pigmentosa - McDermott Will & Emery

Biotech Horama Raises 19M€ to Treat Retinitis Pigmentosa

Overview


Anthony Paronneau provided legal counsel as French biotech company Horama completed a 19M€ fundraising round from four investment firms that will support its lead drug candidate, a gene therapy for retinitis pigmentosa, through clinical trials.